Zymox

Zymox: antiparkinsonian drug from Greece

Zymox is a drug indicated for the treatment of Parkinson's disease and symptomatic parkinsonism. The drug is produced in Greece by Faran Laboratories and belongs to the group of antiparkinsonian dopaminergic drugs.

The active substances of Zymox are levodopa and carbidopa, the international name of which is also used in the name of the drug. Levodopa is a precursor to dopamine, which is a neurotransmitter involved in the regulation of motor activity. Carbidopa also serves as an inhibitor of decarboxylase, which destroys levodopa in the digestive tract and in peripheral tissues, which allows increasing the amount of levodopa entering the brain.

Zymox is available in tablet form, and has several synonyms, including Sindopa, Sinemet, Tidomet and others.

The drug has a number of contraindications and side effects. Contraindications include severe atherosclerosis, hypertension, liver, kidney, blood diseases, glaucoma, melanoma, bronchial asthma, mental illness, uncompensated pathology of the cardiovascular, respiratory, and endocrine systems. Side effects may include choreoathetoid hyperkinesis, arrhythmias, psychotic and paranoid reactions, dyspepsia, dizziness, visual impairment, hemolytic anemia, agranulocytosis, leukopenia, alopecia, allergic reactions, ulceration of the gastrointestinal tract.

The drug may also interact with other drugs, for example, it may enhance the effect of MAO inhibitors and weaken vitamin B6.

Taking Zymox should only be done under the supervision of a doctor, who should periodically monitor the patient’s condition and conduct the necessary tests. The drug limits its use during pregnancy, children under 12 years of age and in the presence of a history of myocardial infarction. Nursing mothers are also advised to stop breastfeeding during treatment.

Thus, Zymox is an effective antiparkinsonian drug that can only be prescribed by a doctor after carefully studying the patient’s medical history and his individual characteristics.